• Roivant President and Immunovant CEO Eric Venker reported the sale of 200,000 common shares on May 22 at a weighted average price of $30.27.
• He also exercised stock options for 200,000 common shares on May 22 at $3.85.
• Venker disposed of 34,483 common shares on May 20 at $32.41.
• He held 1,613,063 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001635088-26-000065), on May 22, 2026, and is solely responsible for the information contained therein.